Table 2

Comparison of the clinical manifestations of patients in various gB genotype groups

CMV gB genotype 1CMV gB genotype 3P value
Mean±SDRange, medianMean±SDRange, median
N (%)11, 78.6%3, 21.4%
Male (n, %)10, 90.9%2, 66.7%0.396
Age at the clinic visit (years)41.55±11.2528–62, 4052.33±14.1937–65, 55
Age at the first onset (years)37±1222–56, 3447±1731–64, 45
Course of disease (years)4.7±2.81–10, 45.7±4.51–10, 6
Bilateral (n, %)1, 9.1%2, 66.7%0.093
Frequency of onset (n/year)1.5±0.81–3, 11.7±0.61–2, 20.209
GC dependence (n, %)7, 63.6%1, 33.3%0.538
Anti-HCMV IgG (s/co)0.94±0.790.24–2.39, 0.670.67±0.710.24–1.49, 0.27
Response to antiviral therapy (n of Cc, %)5, 45.5%1, 33.3%1.000
VA (LogMAR)0.36±0.480.00–1.70, 0.220.23±0.320.00–0.6, 0.10
Ratio of C/D0.59±0.220.3–0.9, 0.50.47±0.120.4–0.6, 0.4
Peak IOP48±541–60, 4848±3.545–52, 48
Corneal endothelial cell loss (%)0.14±0.09−0.03–0.27, 0.120.08±0.09−0.02–0.14, 0.12
KPs (n, %)
 Sheep-fat10, 90.9%2, 66.7%0.396
 Coin-shaped5, 45.5%3, 100%0.209
 Pigmented1, 9.1%2, 66.7%0.093
Tyndall effect (n, %)3, 27.3%2, 66.7%0.505
Iris depigmentation (n, %)8. 72.3%3, 100%1.000
Cataract (n, %)4, 36.4%2, 66.7%0.583
Glaucomatous optic neuropathy (n, %)8, 72.3%1, 33.3%0.505
  • Statistical analysis was performed using Fisher’s exact test.

  • C/D, cup to disk ratio; gB, glycoprotein B; GC, glucocorticoid; HCMV, human cytomegalovirus; IgG, immunoglobulin G; IOP, intraocular pressure; KPs, keratic precipitates; LogMAR, logarithm of mininal angle resolution; n of Cc, number of patients with the 'complete control' outcome; VA, visual acuity.